Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 11, 2011

Takeda Pays Zinfandel $9M Up Front for Rights to Predictive AD Biomarker

  • Takeda Pharmaceutical is paying Zinfandel Pharmaceutical $9 million up front for a worldwide license to the latter’s Tomm40 biomarker assay, which is in development for use in predicting the five-year risk of Alzheimer’s disease in high-risk older adults. The firms will work together to prospectively validate the Tomm40 biomarker as a test of individual risk, and in particular in patients receiving pioglitazone, the active ingredient in Takeda’s marketed type 2 diabetes drug Actos®. Over the last few years pioglitazone has been debated as a potential therapy for Alzheimer disease.

    Under terms of the agreement with Zinfandel Takeda has an exclusive license to the Tomm40 assay along with sublicensing rights for applications including identifying high-risk older adults eligible for clinical trials with pioglitazone. Zinfandel could receive up to $78 million in development milestones on top of the initial signing fee, plus commercial milestones and sales royalties. The firm was established to develop the Tomm40 biomarker, which was discovered by a team led by Allen Roses, M.D., Zinfandel’s CEO.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »